Is it appropriate to give prasugrel (Effient) together with enoxaparin (Lovenox) for antiplatelet therapy after an acute coronary syndrome or percutaneous coronary intervention?

Yes, prasugrel (Effient) and enoxaparin (Lovenox) are routinely used together during acute coronary syndrome management and PCI.

This combination is explicitly recommended in current guidelines and is standard practice for antiplatelet and anticoagulation therapy in ACS patients undergoing PCI. 1, 2

How This Combination Works

The two medications serve complementary but distinct roles:

• Prasugrel (Effient): Oral P2Y12 inhibitor that provides antiplatelet therapy by irreversibly blocking platelet aggregation
• Enoxaparin (Lovenox): Low-molecular-weight heparin (LMWH) that provides anticoagulation by inhibiting thrombin generation

Guideline-Based Recommendations

For NSTE-ACS Patients Undergoing PCI

Antiplatelet therapy 2, 3:

• Prasugrel 60 mg loading dose, then 10 mg daily (Class I, Level B)
• Combined with aspirin 150-300 mg loading dose, then 75-100 mg daily
• Continue for 12 months unless excessive bleeding risk

Anticoagulation during PCI 1, 2:

• Enoxaparin should be considered (Class IIa, Level B) in patients pre-treated with subcutaneous enoxaparin
• If patient already receiving enoxaparin subcutaneously, continue with IV enoxaparin during PCI
• Discontinue parenteral anticoagulation immediately after the procedure (Class IIa, Level C)

Timing and Administration

Prasugrel timing 4:

• Loading dose given once coronary anatomy is known in NSTE-ACS patients
• Can be given before, during, or within 1 hour after PCI
• Do NOT give prasugrel before knowing coronary anatomy in NSTE-ACS (Class III recommendation) 2

Enoxaparin dosing during PCI 1:

• Single bolus of UFH (85 IU/kg, or 60 IU/kg with GP IIb/IIIa inhibitors) if patient on fondaparinux
• Continue enoxaparin IV if pre-treated with subcutaneous enoxaparin

Critical Safety Considerations

Bleeding Risk Management

Prasugrel carries increased bleeding risk 4:

• Contraindicated in patients with prior stroke/TIA
• Not recommended in patients ≥75 years (except high-risk diabetes/prior MI)
• Reduce dose to 5 mg daily if weight <60 kg
• Discontinue 7 days before planned surgery

When combining with enoxaparin 1:

• Do NOT crossover between UFH and LMWH (Class III, Level B)
• Discontinue parenteral anticoagulation immediately post-procedure
• Monitor for bleeding complications

Real-World Evidence

One registry study 5 specifically evaluated the combination of:

• Pre-hospital prasugrel + enoxaparin
• Followed by bivalirudin in the cath lab

Results showed:

• 0% severe GUSTO bleeding in protocol-treated group
• 6.1% MACE rate at 30 days
• Regimen deemed safe in STEMI patients

Practical Algorithm

For NSTE-ACS patients:

1. At presentation: Start aspirin + enoxaparin subcutaneously
2. After diagnostic angiography confirms anatomy suitable for PCI: Give prasugrel 60 mg loading dose
3. During PCI: Continue enoxaparin IV (if already on it) OR give UFH bolus
4. Immediately post-PCI: Stop parenteral anticoagulation
5. Long-term: Continue prasugrel 10 mg daily + aspirin 75-100 mg daily for 12 months

For STEMI patients (primary PCI):

1. At diagnosis: Aspirin + prasugrel 60 mg loading dose can be given together
2. During PCI: Enoxaparin or UFH for procedural anticoagulation
3. Post-procedure: Same as above

Common Pitfalls to Avoid

• Never give prasugrel before knowing coronary anatomy in NSTE-ACS - risk of bleeding if urgent CABG needed 2
• Never switch between UFH and enoxaparin during the same procedure 1
• Never continue parenteral anticoagulation beyond the procedure unless specific indication 1
• Screen for stroke/TIA history - absolute contraindication to prasugrel 4
• Check age and weight - adjust prasugrel dosing accordingly 4

The 2025 ACC/AHA guidelines 3, 6 continue to recommend ticagrelor or prasugrel over clopidogrel for ACS patients undergoing PCI, with prasugrel specifically preferred in NSTE-ACS patients proceeding to PCI 2. The combination with enoxaparin remains a Class IIa recommendation when patients are pre-treated with subcutaneous enoxaparin.